Invion

Invion Gross Profit/Assets

The Gross Profit to Assets Ratio of Invion (IVX.AX) as of Oct 28, 2026 is 4.72 %. In the previous year, Gross Profit to Assets Ratio was -13.60 % — a change of -134.70% (higher).

Gross Profit/Assets

4.72 %

YoY

-134.70%

Last updated:

Gross Profit to Assets Ratio of Invion is 2026 4.72 % . Gross Profit to Assets Ratio of Invion was 2025 -13.60 % . It decreases by -134.70% higher compared to the previous year.

The Invion Gross Profit/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit/Assets
Date
Gross Profit/Assets
Jan 1, 2019
26.81 AUD
Jan 1, 2020
33.27 AUD
Jan 1, 2021
14.37 AUD
Jan 1, 2022
4.84 AUD
Jan 1, 2023
6.33 AUD
Jan 1, 2024
6.49 AUD
Jan 1, 2025
-13.60 AUD
Jan 1, 2026
4.72 AUD
The Invion Gross Profit/Assets history
YEARGross Profit/AssetsYoY
4.72 %-134.70%
-13.60 %-309.43%
6.49 %+2.50%
6.33 %+30.99%
4.84 %-66.34%
14.37 %-56.82%
33.27 %+24.09%
26.81 %+656.36%
3.54 %-116.55%
-21.42 %+117.27%
-9.86 %-82.04%
-54.89 %+288.42%
-14.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Gross Profit to Assets Ratio of Invion is 4.72 % in 2026.

Gross Profit to Assets Ratio of Invion changed from -13.60 % to 4.72 %, representing a -134.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit to Assets Ratio Invion since 2006 – with annual values, charts, and detailed analysis.

Gross Profit/Assets measures how efficiently a company uses its assets to generate gross profit. Research shows it is a strong predictor of future stock returns.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Profit to Assets Ratio's Invion with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Profit to Assets Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Profit to Assets Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Invion

All Key Metrics — Invion